Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
J Headache Pain
; 23(1): 55, 2022 May 11.
Article
in En
| MEDLINE
| ID: mdl-35538414
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Epilepsy
/
Migraine Disorders
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
J Headache Pain
Journal subject:
MEDICINA INTERNA
/
NEUROLOGIA
/
PSICOFISIOLOGIA
Year:
2022
Document type:
Article
Affiliation country: